BioPharma Credit (LSE:BPCR) 3-Year Revenue Growth Rate : 8.40% (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit 3-Year Revenue Growth Rate?

BioPharma Credit's Revenue per Share for the six months ended in Dec. 2022 was $0.09.

During the past 12 months, BioPharma Credit's average Revenue per Share Growth Rate was -37.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 8.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 7 years, the highest 3-Year average Revenue per Share Growth Rate of BioPharma Credit was 14.50% per year. The lowest was -7.20% per year. And the median was 8.40% per year.

Competitive Comparison of BioPharma Credit's 3-Year Revenue Growth Rate

For the Asset Management subindustry, BioPharma Credit's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioPharma Credit's 3-Year Revenue Growth Rate Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, BioPharma Credit's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where BioPharma Credit's 3-Year Revenue Growth Rate falls into.

BioPharma Credit 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

BioPharma Credit (LSE:BPCR) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

BioPharma Credit 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of BioPharma Credit's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioPharma Credit (LSE:BPCR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Gresham Street, 6th Floor, London, GBR, EC2V 7NQ

Website

https://www.bpcruk.com

BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit (LSE:BPCR) Headlines

No Headlines